Nepafenac 0.1% Eye Drop Solution- Solution vs Suspension

Nepafenac 0.1% is a well-established ophthalmic NSAID used to control post-operative pain and inflammation, especially after cataract and other anterior segment surgeries. Traditionally, nepafenac 0.1% is available as a suspension because the active ingredient has low water solubility. While suspensions are effective, they can have a few practical limitations during real-world use. At Able Pharma, we have developed a stable nepafenac 0.1% eye drop solution, created to deliver the advantages of a true solution format while maintaining stability and patient acceptability.

Why a solution format matters

1) Better dose uniformity

Suspensions contain drug particles dispersed in liquid. Even when patients follow “shake well before use”, the shaking intensity and time can vary, which may lead to dose variability.
A solution keeps the drug uniformly dissolved, supporting consistent dosing in every drop throughout the product’s use.

2) Faster availability at the ocular surface

With suspensions, particles must first dissolve in the tear film before the drug can begin moving into ocular tissues. A solution removes this extra step, so the drug is immediately available in dissolved form right after instillation.

3) Improved comfort and a cleaner drop experience

Some patients experience transient blurring or a mild “gritty” feel with suspensions due to particulate matter. A solution can offer a cleaner drop feel, which may support better comfort and compliance, particularly in the early post-operative period.

4) Strong scientific rationale for efficient delivery

Clinical outcomes depend on many factors, but in formulation science it is well understood that dissolved drug can enable more efficient movement across ocular tissues compared to dispersed particles. Some international formulation studies have also reported improved permeation and retention characteristics with nepafenac solution approaches versus suspension references, supporting the rationale for a solution-based system.

Our development approach

Our nepafenac 0.1% solution has been developed using a suitable solubilising excipient system and a robust manufacturing process, focused on key quality expectations:

Stable, uniform solution throughout shelf life
Consistent appearance and performance
Patient-acceptable in-use experience
Process designed for reproducible commercial manufacturing

Conclusion

Nepafenac 0.1% remains a trusted option for post-operative ocular pain and inflammation. Moving from a suspension to a true solution format can offer clear practical advantages, including better dose uniformity, a cleaner drop experience, and faster availability of dissolved drug at the ocular surface. Based on this sound scientific rationale and supportive indications reported in some international formulation studies, a stable nepafenac 0.1% solution represents a meaningful step forward in product design.

With Able Pharma’s nepafenac 0.1% eye drop solution, partners can consider a differentiated ophthalmic NSAID offering that is manufacturing-ready and suitable for building a strong, patient-friendly brand in their target markets.